Continuous administration trial of Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer [EXTENSION OF 700194575]
Phase of Trial: Phase II
Latest Information Update: 16 May 2016
Price : $35 *
At a glance
- Drugs OCV 101 (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors OncoTherapy Science
- 20 Nov 2015 Status changed from active, no longer recruiting to completed, according to University Hospital Medical Information Network - Japan record.
- 31 May 2013 Status changed from completed to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 16 Apr 2013 New trial record